Reducing tablet burden in kidney disease

Reported by Susan Aldridge, PhD, medical journalist

A new trial shows that lathanum carbonate offers a simpler way of controlling phosphate burden in kidney disease.
A high level of phosphorus, known as hyperphosphatemia, is a common complication of end-stage kidney disease. Untreated, it may lead to bone problems and increase the risk of heart disease. But managing hyperphosphatemia can be challenging because it involves taking many tablets - known as phosphate binders - and severe dietary restriction.

A drug called FOSRENOL ® or lanthanum carbonate appears to offer some advantages because fewer tablets need to be taken (one per meal). In a trial carried out by the South Florida Nephrology Group, researchers found that physician and patient satisfaction with treatment increased after 12 weeks of FOSRENOL (for physicians from 52 per cent to 84 per cent and for patients from 67 per cent to 84 per cent). Related research showed that high doses of FOSRENOL as staring therapy allows more rapid control of phosphorus, without adverse effects.

Source
National Kidney Foundation meeting 21st April 2006

Please take a moment to give us your comments. For questions about Health matters you may check our "Questions & Answers" Portal and Service.